Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
about
Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerIntense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expressionChemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomesEvaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection.A novel method of obtaining prostate tissue for gene expression profiling.A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.Adjuvant medical therapy for prostate cancer.Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life.Multimodal approaches to high-risk prostate cancer.Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerIdentification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localRegulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanesChemotherapy for high-risk localized prostate cancer.Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments.The medical management of prostate cancer: a multidisciplinary team approach.Evolving treatment paradigms for locally advanced and metastatic prostate cancer.Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy.Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancerDefining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group.Adjuvant treatment to surgery.Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.Genomic signatures associated with the development, progression, and outcome of prostate cancer.Novel therapeutic strategies in development for prostate cancer.Prostate cancer chemotherapy in the era of targeted therapy.Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.Preoperative therapy for localized prostate cancer: a comprehensive overview.GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism.Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy.Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.The role of chemotherapy and new targeted agents in the management of primary prostate cancer.Pharmacotherapeutic management of locally advanced prostate cancer: current status.The role of surgery in high-risk localised prostate cancer.
P2860
Q27028084-FBE9200D-6BAC-48B6-A967-E918977EE872Q27313709-A52C0BA1-6DF8-482B-8B11-E9AFDA0A2187Q28117805-EC9ECFA3-0E64-485E-BA4A-05C835E65921Q28542841-CB659D8E-1C0F-43CF-A195-56EBBD200C9BQ33247068-2E5D21FF-9C08-433E-A8D5-0C8D9818D3ECQ33338381-6E424645-7853-42FA-9C71-4A0A762AF50CQ33389796-C6545841-2F85-4C60-A3EA-E5F70D29207AQ33631383-5333C055-02E5-4E9A-8392-A2E5CF5DD178Q33758771-18A77C04-AF06-4142-9DEF-CF413F8F7778Q33939310-011EC324-3CF2-46F7-B5C9-D0D76F6A6381Q34111597-C5F9A725-E849-4389-93E3-4B22997626B5Q34618362-4DF8702D-8CA9-483E-82D4-26A3D488CC2FQ34637919-F019B834-7BFB-402A-B5C5-DB513C930594Q34993890-48D11D86-4133-4920-8C9D-F6C93D5367AEQ35112059-F520C6BA-AE26-4FDF-AAAC-19D5EDE71FC7Q35704002-E3AAECFA-860F-472C-90A1-87C28C7A198CQ35856517-5A3C0F02-8204-4B6F-A12F-A0DFF321FB5FQ36421099-149A7ADD-DFCD-4E79-A9A7-4A8ACDD6B926Q36573874-4F1F3A22-DE42-40E5-BBFE-882706FF5DAEQ36586934-30CAD8FB-927A-44A0-B1C2-4E4703E4458EQ36668260-7CFAAB47-7CA5-4B84-813F-7F115B053994Q36740128-397BA47C-843E-4F66-8618-A24D54BE6F3DQ36765820-5C6AD34E-82C1-4675-8817-F248E553979FQ36859714-453BC452-BA87-4FB4-9AF5-7360EF036473Q36861768-C99547EF-A3C2-4D57-92AA-E40F30845F9BQ36973569-C674376B-0A00-43AA-9C0E-42F3C1F8C16CQ37031510-CE7F1396-097C-4904-8021-5CBBF0A6C0E3Q37038977-648219BD-626C-4818-BFB4-969AC335D7D0Q37180864-1D56C579-C207-40DF-ADEF-6B6AF44026C2Q37218730-A67D944C-7F76-4E62-A2E8-C8854ECF2349Q37309238-F78B6881-C3B3-45DD-B30A-F1F4E9941BA1Q37354526-A13F6908-F530-46FA-B8DA-02AB26ECF866Q37398588-D44852E3-3382-4CA3-8C5A-E5C84A31280EQ37463153-ACF954C8-45C2-454B-92AD-793EB63827FFQ37546041-9AE920A4-2D3D-4A0E-9E83-78EF454380D9Q37546045-FB762E50-CF21-4897-8CF9-A45415F7DE7BQ37705424-96F62029-11D4-47D4-9990-6F7979976DC1Q37708171-A43B3022-4EC4-4847-9A8E-758C081C6C80Q37888666-A3FDB055-989A-47D3-AB39-55020E942B67Q37939464-80DBBE6F-EBE9-4219-A8CE-6F45D9560109
P2860
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Neoadjuvant docetaxel before r ...... isk localized prostate cancer.
@ast
Neoadjuvant docetaxel before r ...... isk localized prostate cancer.
@en
Neoadjuvant docetaxel before r ...... isk localized prostate cancer.
@nl
type
label
Neoadjuvant docetaxel before r ...... isk localized prostate cancer.
@ast
Neoadjuvant docetaxel before r ...... isk localized prostate cancer.
@en
Neoadjuvant docetaxel before r ...... isk localized prostate cancer.
@nl
prefLabel
Neoadjuvant docetaxel before r ...... isk localized prostate cancer.
@ast
Neoadjuvant docetaxel before r ...... isk localized prostate cancer.
@en
Neoadjuvant docetaxel before r ...... isk localized prostate cancer.
@nl
P2093
P1476
Neoadjuvant docetaxel before r ...... isk localized prostate cancer.
@en
P2093
Agnieska Szot Barnes
Clare Tempany
Daniel J George
Jerome P Richie
Judith Manola
Phillip G Febbo
Sridhar Shankar
William Catalona
William K Oh
P304
P356
10.1158/1078-0432.CCR-05-0299
P407
P577
2005-07-01T00:00:00Z